|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
protopanaxadiol inhibits the reaction [Scopolamine results in increased activity of ACHE protein] |
CTD |
PMID:29133030 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Bcl2l1 |
BCL2-like 1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of BCL2L1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects expression |
ISO |
protopanaxadiol affects the expression of BIRC5 protein |
CTD |
PMID:31805304 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Casp3 |
caspase 3 |
increases expression affects cleavage |
ISO |
protopanaxadiol results in increased expression of CASP3 mRNA protopanaxadiol affects the cleavage of CASP3 protein |
CTD |
PMID:31805304 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
increases expression affects expression |
ISO |
protopanaxadiol results in increased expression of CASP9 mRNA protopanaxadiol affects the expression of CASP9 protein |
CTD |
PMID:31805304 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccna2 |
cyclin A2 |
increases expression |
ISO |
protopanaxadiol results in increased expression of CCNA2 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of CCNB1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of CCND1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Cdc25a |
cell division cycle 25A |
multiple interactions increases expression |
ISO |
protopanaxadiol results in increased expression of and results in decreased phosphorylation of CDC25A protein protopanaxadiol results in increased expression of CDC25A mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 9:109,704,545...109,722,963
Ensembl chr 9:109,704,647...109,722,963
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression multiple interactions |
ISO |
protopanaxadiol results in increased expression of CDC25C mRNA protopanaxadiol affects the expression of and affects the phosphorylation of CDC25C protein |
CTD |
PMID:31805304 |
|
NCBI chr18:34,866,046...34,884,644
Ensembl chr18:34,866,046...34,884,586
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of CDK1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
ISO |
protopanaxadiol results in increased expression of CDK2 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdk4 |
cyclin dependent kinase 4 |
increases expression |
ISO |
protopanaxadiol results in increased expression of CDK4 mRNA; protopanaxadiol results in increased expression of CDK4 protein |
CTD |
PMID:31805304 |
|
NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
EXP |
protopanaxadiol inhibits the reaction [Scopolamine results in decreased activity of CHAT protein] |
CTD |
PMID:29133030 |
|
NCBI chr14:32,130,160...32,187,866
Ensembl chr14:32,130,160...32,187,946
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases activity |
ISO |
protopanaxadiol results in decreased expression of and results in increased phosphorylation of EGFR protein protopanaxadiol results in decreased activity of EGFR protein |
CTD |
PMID:31805304 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
protopanaxadiol inhibits the reaction [Scopolamine results in decreased expression of EGR1 protein] |
CTD |
PMID:29133030 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
EXP |
protopanaxadiol inhibits the reaction [Scopolamine results in decreased expression of FOS protein] |
CTD |
PMID:29133030 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
EXP |
protopanaxadiol inhibits the reaction [Scopolamine results in decreased expression of JUN protein] |
CTD |
PMID:29133030 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of MAP2K1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation |
ISO |
protopanaxadiol results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:31805304 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation |
ISO |
protopanaxadiol results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:31805304 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of PARP1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Raf1 |
v-raf-leukemia viral oncogene 1 |
increases phosphorylation |
ISO |
protopanaxadiol results in increased phosphorylation of RAF1 protein |
CTD |
PMID:31805304 |
|
NCBI chr 6:115,595,530...115,653,596
Ensembl chr 6:115,595,028...115,653,596
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase polypeptide 1 |
increases expression |
ISO |
protopanaxadiol results in increased expression of RPS6KA1 mRNA |
CTD |
PMID:31805304 |
|
NCBI chr 4:133,574,601...133,615,466
Ensembl chr 4:133,574,601...133,615,108
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
affects expression |
ISO |
protopanaxadiol affects the expression of STAT3 protein |
CTD |
PMID:31805304 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression |
ISO |
protopanaxadiol results in increased expression of TP53 mRNA; protopanaxadiol results in increased expression of TP53 protein |
CTD |
PMID:31805304 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions decreases expression |
ISO |
XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:31916386 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein] |
CTD |
PMID:27387537 |
|
NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007
|
|
G |
Ar |
androgen receptor |
increases degradation multiple interactions |
ISO |
ginsenoside Rg3 results in increased degradation of AR protein ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein] |
CTD |
PMID:22101440 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Areg |
amphiregulin |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of AREG mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of BAX protein] |
CTD |
PMID:26427350 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of BCL2 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
ISO EXP |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]] |
CTD |
PMID:24394491 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions |
EXP ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein] |
CTD |
PMID:34423507 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein] |
CTD |
PMID:27387537 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of BIRC5 mRNA; ginsenoside Rg3 results in decreased expression of BIRC5 protein |
CTD |
PMID:19778801 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor, type 1A |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr14:34,133,018...34,225,335
Ensembl chr14:34,132,691...34,225,298
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of CASP1 protein] |
CTD |
PMID:34423507 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
ginsenoside Rg3 results in increased cleavage of CASP3 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein] |
CTD |
PMID:22101440 PMID:26427350 PMID:31916386 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP8 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP9 protein] |
CTD |
PMID:26427350 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [dimethoxon results in decreased activity of CAT protein] |
CTD |
PMID:26240163 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccn1 |
cellular communication network factor 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of CCN1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 3:145,352,726...145,355,740
Ensembl chr 3:145,352,731...145,355,736
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of CCN2 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
EXP |
[Xiao-Ke-An results in increased abundance of ginsenoside Rg3] which results in decreased activity of DPP4 protein |
CTD |
PMID:32535096 |
|
NCBI chr 2:62,160,417...62,242,635
Ensembl chr 2:62,160,417...62,242,575
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]] |
CTD |
PMID:25824408 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions affects phosphorylation |
ISO |
EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein |
CTD |
PMID:25824408 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Epcam |
epithelial cell adhesion molecule |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of EPCAM mRNA |
CTD |
PMID:31916386 |
|
NCBI chr17:87,943,407...87,958,555
Ensembl chr17:87,943,407...87,958,557
|
|
G |
Fut4 |
fucosyltransferase 4 |
multiple interactions decreases expression |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein] ginsenoside Rg3 results in decreased expression of FUT4 protein |
CTD |
PMID:26427350 |
|
NCBI chr 9:14,659,755...14,663,418
Ensembl chr 9:14,659,616...14,663,689
|
|
G |
Hsf1 |
heat shock factor 1 |
multiple interactions decreases expression |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein] ginsenoside Rg3 results in decreased expression of HSF1 protein |
CTD |
PMID:26427350 |
|
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO EXP |
ginsenoside Rg3 results in increased expression of IL1B protein ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein] ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:14534150 PMID:33050067 PMID:34423507 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of KIT mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382
|
|
G |
Klf4 |
Kruppel-like transcription factor 4 (gut) |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of KLF4 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
|
|
G |
Lats1 |
large tumor suppressor |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of LATS1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr10:7,556,964...7,592,225
Ensembl chr10:7,556,978...7,592,224
|
|
G |
Lats2 |
large tumor suppressor 2 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of LATS2 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr14:57,927,119...57,983,669
Ensembl chr14:57,927,119...57,995,845 Ensembl chr14:57,927,119...57,995,845
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
ginsenoside Rg3 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
multiple interactions |
ISO |
[ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein |
CTD |
PMID:31916386 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA] |
CTD |
PMID:24793912 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [dimethoxon results in increased activity of MPO protein] |
CTD |
PMID:26240163 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of MYC mRNA |
CTD |
PMID:31916386 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of NANOG mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 6:122,684,448...122,691,592
Ensembl chr 6:122,684,448...122,691,592
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions increases activity |
ISO |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein ginsenoside Rg3 results in increased activity of NFKB1 protein |
CTD |
PMID:14534150 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein |
CTD |
PMID:14534150 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:34423507 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]] |
CTD |
PMID:27387537 |
|
NCBI chr11:89,191,464...89,193,385
Ensembl chr11:89,191,464...89,193,158
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions increases expression |
ISO |
Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein] ginsenoside Rg3 results in increased expression of NOS2 mRNA |
CTD |
PMID:14534150 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
ISO EXP |
[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] |
CTD |
PMID:24394491 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions |
ISO |
ginsenoside Rg3 results in increased cleavage of PARP1 protein [ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein] |
CTD |
PMID:22101440 PMID:24793912 PMID:26427350 PMID:31916386 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1, cytosolic |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of PCK1 mRNA |
CTD |
PMID:30144466 |
|
NCBI chr 2:172,994,866...173,001,067
Ensembl chr 2:172,994,841...173,001,066
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of POU5F1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of PPARGC1A mRNA |
CTD |
PMID:30144466 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Prom1 |
prominin 1 |
decreases expression multiple interactions |
ISO |
ginsenoside Rg3 results in decreased expression of PROM1 mRNA XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of PROM1 mRNA] |
CTD |
PMID:31916386 |
|
NCBI chr 5:44,150,963...44,260,850
Ensembl chr 5:44,150,962...44,259,374
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP ISO |
ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein] 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein] |
CTD |
PMID:34423507 |
|
NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO EXP |
[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein ginsenoside Rg3 results in decreased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:14534150 PMID:33050067 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Runx2 |
runt related transcription factor 2 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Sall4 |
spalt like transcription factor 4 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of SALL4 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 2:168,590,252...168,609,121
Ensembl chr 2:168,590,252...168,609,863
|
|
G |
Sirt1 |
sirtuin 1 |
increases activity |
ISO |
ginsenoside Rg3 results in increased activity of SIRT1 protein |
CTD |
PMID:30144466 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Slc6a2 |
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
multiple interactions |
EXP |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein] |
CTD |
PMID:24394491 |
|
NCBI chr 8:93,687,100...93,728,295
Ensembl chr 8:93,686,707...93,728,295
|
|
G |
Slc6a3 |
solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
multiple interactions |
EXP |
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein] |
CTD |
PMID:24394491 |
|
NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:24793912 |
|
NCBI chr18:76,369,898...76,444,819
Ensembl chr18:76,374,651...76,444,034
|
|
G |
Snai1 |
snail family zinc finger 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734
|
|
G |
Sox2 |
SRY (sex determining region Y)-box 2 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of SOX2 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of SP1 protein] |
CTD |
PMID:26427350 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO EXP |
3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein] ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] |
CTD |
PMID:34423507 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Stk3 |
serine/threonine kinase 3 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of STK3 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr15:34,875,645...35,155,990
Ensembl chr15:34,875,642...35,179,067
|
|
G |
Stk4 |
serine/threonine kinase 4 |
increases expression |
ISO |
ginsenoside Rg3 results in increased expression of STK4 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 2:163,916,033...163,997,444
Ensembl chr 2:163,912,242...163,997,444
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:24793912 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Thy1 |
thymus cell antigen 1, theta |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of THY1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
ginsenoside Rg3 results in increased expression of TNF protein ginsenoside Rg3 inhibits the reaction [dimethoxon results in increased expression of TNF protein] ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:14534150 PMID:26240163 PMID:33050067 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]] |
CTD |
PMID:27387537 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions |
ISO |
ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]] |
CTD |
PMID:27387537 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:24793912 |
|
NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of WWTR1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 3:57,363,065...57,483,331
Ensembl chr 3:57,363,070...57,483,331
|
|
G |
Yap1 |
yes-associated protein 1 |
decreases expression |
ISO |
ginsenoside Rg3 results in decreased expression of YAP1 mRNA |
CTD |
PMID:31916386 |
|
NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597
|
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of FOS mRNA |
CTD |
PMID:16204943 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
EXP |
ginsenoside Rh1 results in decreased expression of IL4 |
CTD |
PMID:22855946 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itga4 |
integrin alpha 4 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467
|
|
G |
Itgal |
integrin alpha L |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Jun |
jun proto-oncogene |
decreases activity |
EXP |
ginsenoside Rh1 results in decreased activity of JUN protein |
CTD |
PMID:22855946 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
EXP |
ginsenoside Rh1 results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein] |
CTD |
PMID:32623698 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16557482 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
ginsenoside Rh1 results in increased expression of TFF1 mRNA |
CTD |
PMID:16204943 |
|
NCBI chr17:31,380,369...31,384,034
Ensembl chr17:31,380,369...31,384,251
|
|
G |
Tnf |
tumor necrosis factor |
decreases response to substance multiple interactions decreases expression |
ISO EXP |
ginsenoside Rh1 results in decreased susceptibility to TNF protein ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA] ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] ginsenoside Rh1 results in decreased expression of TNF |
CTD |
PMID:16557482 PMID:21875580 PMID:22855946 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32762018 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Bax |
BCL2-associated X protein |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of BAX protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of BCL2 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp3 |
caspase 3 |
increases cleavage decreases expression |
ISO |
ginsenoside Rh2 results in increased cleavage of CASP3 protein ginsenoside Rh2 results in decreased expression of CASP3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CASP9 protein |
CTD |
PMID:32762018 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of CCND1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC1 protein |
CTD |
PMID:26482938 |
|
NCBI chr 4:129,409,897...129,436,516
Ensembl chr 4:129,409,897...129,436,506
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC2 protein |
CTD |
PMID:26482938 |
|
NCBI chr10:36,850,293...36,877,885
Ensembl chr10:36,850,540...36,877,885
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases expression |
ISO |
ginsenoside Rh2 results in decreased expression of HDAC6 protein |
CTD |
PMID:26482938 |
|
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK1 protein ginsenoside Rh2 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation increases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MAPK3 protein ginsenoside Rh2 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:26482938 PMID:32762018 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
ginsenoside Rh2 results in decreased phosphorylation of MTOR protein |
CTD |
PMID:32762018 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
increases expression |
ISO |
ginsenoside Rh2 results in increased expression of NFKBIA protein |
CTD |
PMID:32762018 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
ginsenoside Rh2 results in increased expression of and results in decreased phosphorylation of RELA protein |
CTD |
PMID:32762018 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
estriol 17-glucuronide inhibits the reaction [ABCB1 results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:9794924 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
multiple interactions increases expression |
EXP ISO |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]]; Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]] Escin results in increased expression of ACACA mRNA Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of ACACA mRNA] |
CTD |
PMID:36905866 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
ISO EXP |
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ACOX1 mRNA] ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]] |
CTD |
PMID:36905866 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
EXP ISO |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]]; ATG5 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG5 protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of ATG5 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG5 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG5 protein] Escin results in increased expression of ATG5 protein |
CTD |
PMID:36905866 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
EXP ISO |
Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG7 protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of ATG7 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG7 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of ATG7 protein] |
CTD |
PMID:36905866 |
|
NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions increases expression |
EXP ISO |
Escin inhibits the reaction [Dietary Fats results in decreased expression of BECN1 protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of BECN1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of BECN1 protein]] Escin results in increased expression of BECN1 protein |
CTD |
PMID:36905866 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
increases expression multiple interactions |
ISO EXP |
Escin results in increased expression of CPT1A mRNA ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]] |
CTD |
PMID:36905866 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
EXP ISO |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of CPT2 mRNA] |
CTD |
PMID:36905866 |
|
NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases activity increases expression |
ISO |
Aescin increased activity of cyp1a2 protein enzyme in rat plasma Aescin increased expression of Cyp1a2 mRNA in rat liver |
RGD |
PMID:24252494 PMID:24252494 |
RGD:401900603, RGD:401900603 |
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions decreases expression |
EXP |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]]; Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]] Escin results in decreased expression of FAS mRNA |
CTD |
PMID:36905866 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
EXP ISO |
Escin results in increased expression of GCLC protein Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLC protein] Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLC protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of GCLC protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLC protein]] |
CTD |
PMID:36905866 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP ISO |
Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLM protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLM protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of GCLM protein] Escin results in increased expression of GCLM protein |
CTD |
PMID:36905866 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]; Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]; Escin inhibits the reaction [tyloxapol results in increased expression of GPT protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]] |
CTD |
PMID:36905866 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
Escin results in increased expression of HMOX1 protein Escin inhibits the reaction [Dietary Fats results in decreased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of HMOX1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of HMOX1 protein] |
CTD |
PMID:36905866 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions increases expression |
EXP ISO |
Escin inhibits the reaction [Dietary Fats results in increased expression of KEAP1 protein]; Escin inhibits the reaction [tyloxapol results in increased expression of KEAP1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of KEAP1 protein]] Escin results in increased expression of KEAP1 protein Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of KEAP1 protein] |
CTD |
PMID:36905866 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
EXP ISO |
ATG5 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]]; Escin inhibits the reaction [tyloxapol results in increased lipidation of MAP1LC3B protein]; Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]; NFE2L2 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]] Escin results in increased lipidation of MAP1LC3B protein |
CTD |
PMID:36905866 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Myl9 |
myosin, light polypeptide 9, regulatory |
multiple interactions |
ISO |
[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein; [Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:29660437 |
|
NCBI chr 2:156,617,373...156,623,578
Ensembl chr 2:156,617,340...156,623,578
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
increases expression multiple interactions |
EXP ISO |
Escin results in increased expression of NFE2L2 protein Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NFE2L2 protein]; Escin results in increased expression of and affects the localization of NFE2L2 protein Escin inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ACOX1 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG5 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of ATG7 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of BECN1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of CPT2 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLC protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of GCLM protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of HMOX1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of NQO1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of ACACA mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of GPT protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of KEAP1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]]; NFE2L2 protein affects the reaction [Escin promotes the reaction [Dietary Fats results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:36905866 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
increases expression multiple interactions |
ISO EXP |
Escin results in increased expression of NQO1 protein Escin inhibits the reaction [Dietary Fats results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of NQO1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of NQO1 protein] |
CTD |
PMID:36905866 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]]; Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]; Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]; Escin inhibits the reaction [tyloxapol results in decreased expression of PPARA protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in decreased expression of PPARA protein]] |
CTD |
PMID:36905866 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO |
Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in decreased expression of PPARG protein] Escin results in increased expression of PPARG protein |
CTD |
PMID:36905866 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein] |
CTD |
PMID:29660437 |
|
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP ISO |
ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]]; Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]; Escin inhibits the reaction [tyloxapol results in increased expression of SQSTM1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SQSTM1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SQSTM1 protein] |
CTD |
PMID:36905866 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
EXP ISO |
Escin results in increased expression of SREBF1 mRNA; Escin results in increased expression of SREBF1 protein ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; ATG5 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]]; Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]; Escin inhibits the reaction [tyloxapol results in increased expression of SREBF1 protein]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]]; NFE2L2 protein affects the reaction [Escin inhibits the reaction [Dietary Fats results in increased expression of SREBF1 protein]] Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 mRNA]; Escin inhibits the reaction [[Palmitic Acid co-treated with Oleic Acid] results in increased expression of SREBF1 protein] |
CTD |
PMID:36905866 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:25913072 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:25913072 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and affects the localization of JUN protein]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of JUN protein modified form] |
CTD |
PMID:25913072 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Map2k7 |
mitogen-activated protein kinase kinase 7 |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAP2K7 protein] |
CTD |
PMID:25913072 |
|
NCBI chr 8:4,288,740...4,297,897
Ensembl chr 8:4,288,740...4,297,897 Ensembl chr 8:4,288,740...4,297,897
|
|
G |
Map3k7 |
mitogen-activated protein kinase kinase kinase 7 |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAP3K7 protein] |
CTD |
PMID:25913072 |
|
NCBI chr 4:31,963,659...32,023,470
Ensembl chr 4:31,964,097...32,023,467
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:25913072 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:25913072 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein] |
CTD |
PMID:25913072 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; alpha-chaconine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:25913072 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; alpha-chaconine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:25913072 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in increased expression of BAD mRNA]; alpha-solamargine inhibits the reaction [Sevoflurane results in increased expression of BAD protein] |
CTD |
PMID:35350913 |
|
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of BCL2L1 mRNA]; alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of BCL2L1 protein] |
CTD |
PMID:35350913 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bdnf |
brain derived neurotrophic factor |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of BDNF protein] |
CTD |
PMID:35350913 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in increased cleavage of CASP3 protein]; alpha-solamargine inhibits the reaction [Sevoflurane results in increased expression of CASP3 mRNA] |
CTD |
PMID:35350913 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of CREB1 protein] |
CTD |
PMID:35350913 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of DLG4 protein] |
CTD |
PMID:35350913 |
|
NCBI chr11:69,908,029...69,938,107
Ensembl chr11:69,907,768...69,938,348
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased phosphorylation of and affects the localization of FOXO3 protein]; alpha-solamargine inhibits the reaction [Sevoflurane results in decreased phosphorylation of FOXO3 protein] |
CTD |
PMID:35350913 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of GCLC protein] |
CTD |
PMID:35350913 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of GCLM mRNA] |
CTD |
PMID:35350913 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in increased expression of HMGB1 mRNA] |
CTD |
PMID:35350913 |
|
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of HMOX1 mRNA]; alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of HMOX1 protein] |
CTD |
PMID:35350913 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in increased expression of IL1B mRNA] |
CTD |
PMID:35350913 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of NQO1 mRNA]; alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of NQO1 protein] |
CTD |
PMID:35350913 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased phosphorylation of NTRK2 protein] |
CTD |
PMID:35350913 |
|
NCBI chr13:58,954,363...59,281,782
Ensembl chr13:58,954,383...59,281,784
|
|
G |
Prrx1 |
paired related homeobox 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of PRRX1 protein] |
CTD |
PMID:35350913 |
|
NCBI chr 1:163,072,688...163,142,714
Ensembl chr 1:163,072,688...163,141,279
|
|
G |
Sypl1 |
synaptophysin like 1 |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in decreased expression of SYPL1 protein] |
CTD |
PMID:35350913 |
|
NCBI chr12:33,003,874...33,029,503
Ensembl chr12:33,003,890...33,029,859
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
alpha-solamargine inhibits the reaction [Sevoflurane results in increased expression of TNF mRNA] |
CTD |
PMID:35350913 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:32991863 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:32991863 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BECN1 protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BECN1 protein] |
CTD |
PMID:34051206 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:32991863 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:32991863 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein] |
CTD |
PMID:34051206 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases secretion |
ISO |
anemoside B4 results in decreased secretion of CCL2 protein |
CTD |
PMID:36084722 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of CHUK protein] |
CTD |
PMID:32991863 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:32991863 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; anemoside B4 inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:32991863 PMID:34051206 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:34051206 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor 1 |
decreases phosphorylation |
ISO |
anemoside B4 results in decreased phosphorylation of ITPR1 protein |
CTD |
PMID:36084722 |
|
NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32991863 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32991863 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:32991863 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:32991863 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased expression of NOS2 protein] |
CTD |
PMID:32991863 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
decreases phosphorylation |
ISO |
anemoside B4 results in decreased phosphorylation of PLCG1 protein |
CTD |
PMID:36084722 |
|
NCBI chr 2:160,573,230...160,617,680
Ensembl chr 2:160,573,220...160,617,680
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased expression of PTGS2 protein] |
CTD |
PMID:32991863 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] |
CTD |
PMID:32991863 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of SQSTM1 protein]]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of SQSTM1 protein] |
CTD |
PMID:34051206 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
anemoside B4 results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:36084722 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases secretion |
EXP ISO |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; anemoside B4 inhibits the reaction [Cisplatin results in increased expression of TNF protein]; anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] anemoside B4 results in decreased secretion of TNF protein |
CTD |
PMID:32991863 PMID:34051206 PMID:36084722 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Bdnf |
brain derived neurotrophic factor |
increases expression multiple interactions |
ISO |
asiaticoside results in increased expression of BDNF mRNA asiaticoside inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
asiaticoside inhibits the reaction [Rotenone results in decreased activity of CAT protein] |
CTD |
PMID:28238857 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
decreases activity |
ISO |
asiaticoside results in decreased activity of CYP2C19 protein |
CTD |
PMID:21349323 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions |
ISO |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of MAPK14 protein] |
CTD |
PMID:28238857 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[asiaticoside co-treated with Rotenone] results in decreased expression of MTOR protein |
CTD |
PMID:28238857 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Ngf |
nerve growth factor |
increases expression multiple interactions |
ISO |
asiaticoside results in increased expression of NGF protein asiaticoside inhibits the reaction [Rotenone results in decreased expression of NGF protein] |
CTD |
PMID:28238857 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase 1 |
multiple interactions |
ISO |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 mRNA]; asiaticoside inhibits the reaction [Rotenone results in decreased expression of PDPK1 protein] |
CTD |
PMID:28238857 |
|
NCBI chr17:24,292,654...24,370,957
Ensembl chr17:24,292,654...24,369,898
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
asiaticoside inhibits the reaction [Rotenone results in increased expression of PEBP1 mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr 5:117,420,716...117,425,629
Ensembl chr 5:117,420,719...117,425,690
|
|
G |
Pik3r6 |
phosphoinositide-3-kinase regulatory subunit 5 |
multiple interactions |
ISO |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of PIK3R6 mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr11:68,393,845...68,443,524
Ensembl chr11:68,393,845...68,443,524
|
|
G |
Slc18a2 |
solute carrier family 18 (vesicular monoamine), member 2 |
multiple interactions |
ISO |
asiaticoside inhibits the reaction [Rotenone results in decreased expression of SLC18A2 mRNA] |
CTD |
PMID:28238857 |
|
NCBI chr19:59,249,310...59,284,444
Ensembl chr19:59,249,328...59,284,444
|
|
G |
Stx1a |
syntaxin 1A (brain) |
multiple interactions |
ISO |
[Rotenone co-treated with asiaticoside] results in decreased expression of STX1A mRNA |
CTD |
PMID:28238857 |
|
NCBI chr 5:135,051,473...135,079,954
Ensembl chr 5:135,052,336...135,079,954
|
|
G |
Synj1 |
synaptojanin 1 |
multiple interactions |
ISO |
[asiaticoside co-treated with Rotenone] results in decreased expression of SYNJ1 mRNA |
CTD |
PMID:28238857 |
|
NCBI chr16:90,732,980...90,810,543
Ensembl chr16:90,732,980...90,808,196
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
[asiaticoside co-treated with Rotenone] results in decreased expression of TH protein |
CTD |
PMID:28238857 |
|
NCBI chr 7:142,446,516...142,453,732
Ensembl chr 7:142,446,489...142,484,865
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of AKT1 mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:32344236 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression |
EXP |
astragaloside A results in increased expression of AQP9 mRNA; astragaloside A results in increased expression of AQP9 protein |
CTD |
PMID:37918281 |
|
NCBI chr 9:71,017,941...71,075,170
Ensembl chr 9:71,017,941...71,075,964
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of ATP2A2 protein]; astragaloside A inhibits the reaction [Isoproterenol results in decreased expression of ATP2A2 mRNA] |
CTD |
PMID:17509559 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein] |
CTD |
PMID:22278385 PMID:33285147 PMID:36322813 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of BCL2 protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein] |
CTD |
PMID:33285147 PMID:36322813 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcs1l |
BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCS1L protein] |
CTD |
PMID:22278385 |
|
NCBI chr 1:74,627,448...74,631,602
Ensembl chr 1:74,627,448...74,631,602
|
|
G |
Cacna1c |
calcium channel, voltage-dependent, L type, alpha 1C subunit |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of CACNA1C protein] |
CTD |
PMID:33285147 |
|
NCBI chr 6:118,564,201...119,174,345
Ensembl chr 6:118,564,201...119,173,851
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CASP3 protein modified form] astragaloside A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:22278385 PMID:30842369 PMID:33285147 PMID:36322813 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
astragaloside A results in increased expression of CCND1 protein |
CTD |
PMID:37918281 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of CHUK protein] |
CTD |
PMID:33285147 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
decreases expression multiple interactions |
EXP ISO |
astragaloside IV decreases expression Dusp5 mRNA and protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate increases expression of DUSP5 mRNA and protein in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of EGFR mRNA |
CTD |
PMID:32344236 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of FTH1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of GJA4 protein] |
CTD |
PMID:36322813 |
|
NCBI chr 4:127,205,213...127,207,832
Ensembl chr 4:127,205,214...127,207,832
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [bisphenol A results in decreased activity of GLUL protein] |
CTD |
PMID:34434659 |
|
NCBI chr 1:153,775,692...153,785,469
Ensembl chr 1:153,775,690...153,785,469
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of GPT protein] |
CTD |
PMID:30842369 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Grin2a |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2A mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr16:9,385,765...9,813,744
Ensembl chr16:9,385,762...9,813,424
|
|
G |
Grin2b |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [bisphenol A affects the expression of GRIN2B mRNA] |
CTD |
PMID:34434659 |
|
NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509
|
|
G |
H19 |
H19, imprinted maternally expressed transcript |
increases expression multiple interactions |
EXP ISO |
astragaloside IV increases expression H19 RNA in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases expression of H19 RNA in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 7:142,129,267...142,131,883
Ensembl chr 7:142,129,262...142,133,957
|
|
G |
Hdac9 |
histone deacetylase 9 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of BCL2 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of BAX protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of HDAC9 protein] |
CTD |
PMID:36322813 |
|
NCBI chr12:34,097,579...34,967,094
Ensembl chr12:34,097,579...34,967,094
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein astragaloside A results in increased expression of HMOX1 mRNA; astragaloside A results in increased expression of HMOX1 protein |
CTD |
PMID:25422538 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL1B protein; astragaloside A inhibits the reaction [Cisplatin results in increased expression of IL1B protein]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL1B protein] |
CTD |
PMID:25604657 PMID:30842369 PMID:32344236 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of IL6 protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of IL6 protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of IL6 protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Khdrbs1 |
KH domain containing, RNA binding, signal transduction associated 1 |
decreases expression multiple interactions |
EXP ISO |
astragaloside IV decreases expression of Khdrbs1 protein in thoracic aorta astragaloside IV inhibits the reaction [beta-Glycerophosphate astragaloside IV increases expression of KHDRBS1 protein in Vascular smooth muscle cells] |
RGD |
PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 4:129,596,143...129,637,402
Ensembl chr 4:129,596,957...129,636,096
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [bisphenol A results in increased expression of MAOA protein] |
CTD |
PMID:33666843 |
|
NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33285147 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33285147 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of MMP9 protein |
CTD |
PMID:32344236 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in increased activity of MPO protein] |
CTD |
PMID:25604657 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases phosphorylation |
ISO EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of and results in decreased phosphorylation of MTOR protein; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MTOR mRNA astragaloside IV inhibits the reaction [beta-Glycerophosphate decreases phoshorylation of MTOR protein in Vascular smooth muscle cells] astragaloside IV increases phosphorylation Mtor protein in thoracic aorta |
CTD RGD |
PMID:32344236 PMID:30529164 PMID:30529164 |
RGD:243048424, RGD:243048424 |
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Muc5ac |
mucin 5, subtypes A and C, tracheobronchial/gastric |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5AC mRNA; [paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of MUC5AC protein |
CTD |
PMID:32344236 |
|
NCBI chr 7:141,342,695...141,372,964
Ensembl chr 7:141,342,709...141,372,968
|
|
G |
Muc5b |
mucin 5, subtype B, tracheobronchial |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased expression of MUC5B mRNA |
CTD |
PMID:32344236 |
|
NCBI chr 7:141,392,796...141,426,826
Ensembl chr 7:141,392,807...141,426,821
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions affects localization |
EXP |
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein astragaloside A affects the localization of NFE2L2 protein |
CTD |
PMID:25422538 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of NFKBIA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nfkbib |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of NFKBIB protein] |
CTD |
PMID:25604657 |
|
NCBI chr 7:28,457,676...28,466,069
Ensembl chr 7:28,457,676...28,466,937
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein] |
CTD |
PMID:30842369 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
astragaloside A results in increased expression of PCNA protein |
CTD |
PMID:37918281 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Pln |
phospholamban |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Isoproterenol results in decreased phosphorylation of PLN protein] |
CTD |
PMID:17509559 |
|
NCBI chr10:53,213,782...53,222,095
Ensembl chr10:53,213,763...53,222,083
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases expression |
ISO |
Astragaloside IV increases expression of Ptpn1 protein in the hypothalamus |
RGD |
PMID:29562733 |
RGD:401976390 |
NCBI chr 2:167,772,670...167,821,305
Ensembl chr 2:167,773,977...167,821,305
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Taurocholic Acid affects the localization of RELA protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased phosphorylation of RELA protein] |
CTD |
PMID:25604657 PMID:33285147 PMID:36322813 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rho |
rhodopsin |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RHO mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 6:115,903,741...115,916,999
Ensembl chr 6:115,908,709...115,916,997
|
|
G |
Rpe65 |
retinal pigment epithelium 65 |
multiple interactions |
EXP |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of RPE65 mRNA] |
CTD |
PMID:33285147 |
|
NCBI chr 3:159,304,712...159,330,944
Ensembl chr 3:159,304,812...159,330,958
|
|
G |
Slc11a2 |
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of SLC11A2 protein] |
CTD |
PMID:33285147 |
|
NCBI chr15:100,285,779...100,322,090
Ensembl chr15:100,285,779...100,322,953
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in decreased expression of SOD1 protein] |
CTD |
PMID:25604657 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
astragaloside A promotes the reaction [Taurocholic Acid results in decreased expression of SOD2 protein]; astragaloside A promotes the reaction [Taurocholic Acid results in increased expression of SOD2 mRNA] |
CTD |
PMID:25604657 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein] |
CTD |
PMID:30842369 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TFRC protein] |
CTD |
PMID:33285147 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Timp1 |
tissue inhibitor of metalloproteinase 1 |
multiple interactions |
ISO |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] affects the secretion of TIMP1 protein |
CTD |
PMID:32344236 |
|
NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
[paeonol co-treated with icariin co-treated with nobiletin co-treated with Ginsenosides co-treated with astragaloside A] results in decreased secretion of TNF protein; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF mRNA]; astragaloside A inhibits the reaction [Taurocholic Acid results in increased expression of TNF protein] astragaloside A inhibits the reaction [HDAC9 protein promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein]]; astragaloside A inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of TNF protein] astragaloside A inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein] |
CTD |
PMID:25604657 PMID:32344236 PMID:33285147 PMID:36322813 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tph2 |
tryptophan hydroxylase 2 |
multiple interactions |
ISO |
astragaloside A affects the reaction [bisphenol A affects the expression of TPH2 mRNA] |
CTD |
PMID:33666843 |
|
NCBI chr10:114,914,546...115,020,927
Ensembl chr10:114,914,546...115,020,927
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[bacoside A co-treated with Plant Preparations] inhibits the reaction [Dichlorvos results in decreased expression of ACHE protein] |
CTD |
PMID:27899289 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
[bacoside A co-treated with Plant Preparations] inhibits the reaction [Dichlorvos results in decreased expression of BCHE protein] |
CTD |
PMID:27899289 |
|
NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
ISO |
bacoside A results in increased activity of CAT protein bacoside A inhibits the reaction [Tobacco Smoke Pollution results in decreased activity of CAT protein] |
CTD |
PMID:16226278 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
bacoside A inhibits the reaction [Tobacco Smoke Pollution results in decreased activity of CP protein] |
CTD |
PMID:16226278 |
|
NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA1 mRNA] |
CTD |
PMID:20821261 |
|
NCBI chr11:42,021,766...42,073,893
Ensembl chr11:42,021,766...42,073,757
|
|
G |
Gabra5 |
gamma-aminobutyric acid type A receptor subunit alpha 5 |
multiple interactions |
ISO |
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA] |
CTD |
PMID:20821261 |
|
NCBI chr 7:57,057,417...57,240,808
Ensembl chr 7:57,057,420...57,159,807
|
|
G |
Gabrd |
gamma-aminobutyric acid (GABA) A receptor, subunit delta |
multiple interactions |
ISO |
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRD mRNA] |
CTD |
PMID:20821261 |
|
NCBI chr 4:155,469,437...155,482,528
Ensembl chr 4:155,469,437...155,482,569
|
|
G |
Gsr |
glutathione reductase |
increases activity multiple interactions |
ISO |
bacoside A results in increased activity of GSR protein bacoside A inhibits the reaction [Tobacco Smoke Pollution results in decreased activity of GSR protein] |
CTD |
PMID:16226278 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
bacoside A inhibits the reaction [Diethylnitrosamine results in increased expression of and results in increased activity of MMP2 protein] |
CTD |
PMID:20084675 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
bacoside A inhibits the reaction [Diethylnitrosamine results in increased expression of and results in increased activity of MMP9 protein] |
CTD |
PMID:20084675 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions |
ISO |
beta-solamarine results in increased expression of BAX protein beta-solamarine promotes the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:17619073 PMID:20647040 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
beta-solamarine results in decreased expression of BCL2 protein |
CTD |
PMID:17619073 PMID:20647040 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression |
ISO |
beta-solamarine results in decreased expression of BCL2L1 protein |
CTD |
PMID:17619073 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases activity multiple interactions |
ISO |
beta-solamarine results in increased cleavage of CASP3 protein beta-solamarine results in increased activity of CASP3 protein beta-solamarine promotes the reaction [Cisplatin results in increased activity of CASP3 protein] |
CTD |
PMID:17619073 PMID:20647040 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
beta-solamarine promotes the reaction [Cisplatin results in increased activity of CASP8 protein] beta-solamarine results in increased activity of CASP8 protein |
CTD |
PMID:17619073 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
increases activity increases cleavage multiple interactions |
ISO |
beta-solamarine results in increased activity of CASP9 protein beta-solamarine results in increased cleavage of CASP9 protein beta-solamarine promotes the reaction [Cisplatin results in increased activity of CASP9 protein] |
CTD |
PMID:17619073 PMID:20647040 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ctsb |
cathepsin B |
affects localization |
ISO |
beta-solamarine affects the localization of CTSB protein |
CTD |
PMID:20647040 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
beta-solamarine results in increased expression of FADD protein |
CTD |
PMID:17619073 |
|
NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
beta-solamarine results in increased expression of FAS protein |
CTD |
PMID:17619073 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression |
ISO |
beta-solamarine results in increased expression of TNFRSF1A protein |
CTD |
PMID:17619073 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
beta-solamarine results in increased expression of TRADD protein |
CTD |
PMID:17619073 |
|
NCBI chr 8:105,985,207...105,991,226
Ensembl chr 8:105,984,918...105,991,241
|
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression |
ISO |
araloside A results in decreased expression of BCL2 protein |
CTD |
PMID:31004595 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression decreases secretion |
ISO |
araloside A results in decreased expression of IL1B mRNA araloside A results in decreased secretion of IL1B protein |
CTD |
PMID:31004595 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
decreases secretion decreases expression |
ISO |
araloside A results in decreased secretion of IL6 protein araloside A results in decreased expression of IL6 mRNA |
CTD |
PMID:31004595 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
decreases phosphorylation |
ISO |
araloside A results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:31004595 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
decreases phosphorylation |
ISO |
araloside A results in decreased phosphorylation of RELA protein |
CTD |
PMID:31004595 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:25073091 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] |
CTD |
PMID:25073091 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP12 mRNA] |
CTD |
PMID:25073091 |
|
NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
multiple interactions |
EXP |
[Xiao-Ke-An results in increased abundance of ginsenoside Ro] which results in decreased activity of DPP4 protein |
CTD |
PMID:32535096 |
|
NCBI chr 2:62,160,417...62,242,635
Ensembl chr 2:62,160,417...62,242,575
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation |
EXP |
ginsenoside Ro results in increased phosphorylation of GSK3B protein |
CTD |
PMID:32535096 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HSPA5 protein] |
CTD |
PMID:25073091 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Lpl |
lipoprotein lipase |
increases secretion |
EXP |
ginsenoside Ro results in increased secretion of LPL protein |
CTD |
PMID:8988629 |
|
NCBI chr 8:69,333,207...69,359,584
Ensembl chr 8:69,333,143...69,360,100
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of SIRT1 protein] |
CTD |
PMID:25073091 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
chikusetsusaponin V inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of SOD2 mRNA] |
CTD |
PMID:25073091 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression |
EXP |
cycloastragenol results in increased expression of AQP9 mRNA; cycloastragenol results in increased expression of AQP9 protein |
CTD |
PMID:37918281 |
|
NCBI chr 9:71,017,941...71,075,170
Ensembl chr 9:71,017,941...71,075,964
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Arhgap17 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 7:122,878,372...122,969,171
Ensembl chr 7:122,878,441...122,969,138
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Bax protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
cycloastragenol results in increased expression of CCND1 protein |
CTD |
PMID:37918281 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased secretion of CXCL15 protein] |
CTD |
PMID:37579952 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Dsc2 |
desmocollin 2 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Dsc2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:20,163,690...20,192,611
Ensembl chr18:20,163,690...20,192,611
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Gsk3b protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Ifng protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ikbkg |
inhibitor of kappaB kinase gamma |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Ikbkg protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr X:73,436,883...73,498,013
Ensembl chr X:73,436,896...73,497,460
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il10 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il17 protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il1b protein in spleenocytes and peripheral blood] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Il4 protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Il6 protein in spleenocytes and peripheral blood] cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased secretion of IL6 protein] |
CTD RGD |
PMID:37579952 PMID:32068187 |
RGD:267358468 |
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased secretion of MMP9 protein] |
CTD |
PMID:37579952 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
mt-Co2 |
cytochrome c oxidase II, mitochondrial |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Mt-co2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr MT:7,013...7,696
Ensembl chr MT:7,013...7,696
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP |
cycloastragenol results in increased expression of PCNA protein |
CTD |
PMID:37918281 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Plcg1 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 2:160,573,230...160,617,680
Ensembl chr 2:160,573,220...160,617,680
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Rhoa protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr 9:108,183,359...108,215,142
Ensembl chr 9:108,183,328...108,215,133
|
|
G |
Rit2 |
Ras-like without CAAX 2 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Rit2 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:31,107,367...31,450,181
Ensembl chr18:31,106,542...31,450,343
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
EXP |
cycloastragenol inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TERT protein]; cycloastragenol inhibits the reaction [Benzo(a)pyrene results in decreased expression of TERT protein] |
CTD |
PMID:37579952 |
|
NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction increases expression of Tnf protein in spleen] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
cycloastragenol inhibits the reaction [acute myocardial infarction decreases expression of Zeb1 protein in myocardium] |
RGD |
PMID:32068187 |
RGD:267358468 |
NCBI chr18:5,591,330...5,775,468
Ensembl chr18:5,591,860...5,775,467
|
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
EXP |
Digitonin results in increased expression of CCNB1 protein |
CTD |
PMID:36030841 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
Digitonin results in increased expression of CCND1 protein |
CTD |
PMID:36030841 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in decreased expression of CDH5 protein] |
CTD |
PMID:31404653 |
|
NCBI chr 8:104,828,247...104,871,136
Ensembl chr 8:104,828,257...104,871,143
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
decreases expression |
EXP |
Digitonin results in decreased expression of CDKN1A protein |
CTD |
PMID:36030841 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
decreases expression |
EXP |
Digitonin results in decreased expression of CDKN1B protein |
CTD |
PMID:36030841 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
increases expression |
EXP |
Digitonin results in increased expression of CYP2B10 protein |
CTD |
PMID:36030841 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
increases expression |
EXP |
Digitonin results in increased expression of CYP3A11 protein |
CTD |
PMID:36030841 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Etv2 |
ets variant 2 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in decreased expression of CDH5 protein]; Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in increased expression of SPN protein] |
CTD |
PMID:31404653 |
|
NCBI chr 7:30,333,041...30,335,934
Ensembl chr 7:30,333,041...30,335,277
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in decreased expression of CDH5 protein]; Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in increased expression of SPN protein] |
CTD |
PMID:31404653 |
|
NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014
|
|
G |
Hexb |
hexosaminidase B |
multiple interactions increases activity |
EXP |
1,2-dioleoyl-sn-glycero-3-phosphoglycerol inhibits the reaction [Digitonin results in increased activity of HEXB protein] |
CTD |
PMID:36860548 |
|
NCBI chr13:97,312,839...97,334,865
Ensembl chr13:97,312,839...97,334,865
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
decreases expression |
ISO |
Digitonin results in decreased expression of HIF1A protein |
CTD |
PMID:34717917 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Nek2 |
NIMA (never in mitosis gene a)-related expressed kinase 2 |
increases expression |
EXP |
Digitonin results in increased expression of NEK2 protein |
CTD |
PMID:36030841 |
|
NCBI chr 1:191,553,622...191,565,161
Ensembl chr 1:191,553,556...191,565,162
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
decreases expression |
EXP |
Digitonin results in decreased expression of RBL2 protein |
CTD |
PMID:36030841 |
|
NCBI chr 8:91,796,685...91,850,472
Ensembl chr 8:91,796,685...91,850,472
|
|
G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
multiple interactions |
ISO |
Digitonin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
Digitonin results in increased expression of SLCO1A4 protein |
CTD |
PMID:36030841 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Spn |
sialophorin |
multiple interactions |
ISO |
Digitonin inhibits the reaction [[ETV2 protein co-treated with GATA2 protein] results in increased expression of SPN protein] |
CTD |
PMID:31404653 |
|
NCBI chr 7:126,731,404...126,743,785
Ensembl chr 7:126,731,404...126,736,995
|
|
|
G |
Abca8b |
ATP-binding cassette, sub-family A member 8b |
multiple interactions |
ISO |
Digoxin inhibits the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr11:109,823,016...109,886,642
Ensembl chr11:109,823,016...109,886,671
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
decreases uptake affects uptake increases uptake multiple interactions increases export increases transport affects secretion affects binding affects abundance increases expression affects transport |
ISO EXP |
ABCB1 protein results in decreased uptake of Digoxin ABCB1A protein affects the uptake of Digoxin ABCB1 protein results in increased uptake of Digoxin 18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Digoxin results in increased expression of ABCB1 protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Digoxin results in increased expression of ABCB1 mRNA]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Digoxin results in increased expression of ABCB1 protein]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [citronellal results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [citronellol results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Cyclosporine binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Digoxin results in increased expression of ABCB1] which results in decreased susceptibility to Doxorubicin; [Elacridar binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Elacridar results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; [isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; [Ketoconazole binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Ketoconazole results in decreased activity of ABCB1 protein] which results in increased uptake of Digoxin; [Plant Extracts results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [valspodar results in decreased activity of ABCB1 protein] which results in decreased transport of Digoxin; [Verapamil binds to and results in decreased activity of ABCB1 protein] which results in decreased export of Digoxin; [Verapamil results in decreased activity of ABCB1 protein] which results in decreased transport of Digoxin; ABCB1 protein binds to and affects the metabolism of Digoxin; abietic acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Amiodarone inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; benidipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Bepridil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; beta-pinene inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Bisoprolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Capsaicin affects the reaction [ABCB1 protein results in increased export of Digoxin]; Carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; citronellal inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; citronellol inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; cucurbitacin I inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Curcumin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; cyazofamid affects the reaction [ABCB1 protein results in increased uptake of Digoxin]; dehydroandrographolide inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; desethylamiodarone inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Diazinon affects the reaction [ABCB1 protein results in increased transport of Digoxin]; Digoxin inhibits the reaction [ABCB1 protein results in increased transport of quinidinium]; Diltiazem inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Doxazosin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; efonidipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Emodin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Fusidic Acid inhibits the reaction [ABCB1 protein results in increased export of Digoxin]; gamma-terpinene inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; gingerol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Itraconazole inhibits the reaction [ABCB1 protein affects the transport of Digoxin]; Ketoconazole inhibits the reaction [ABCB1 protein affects the transport of Digoxin]; Ketoconazole inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; KN 93 inhibits the reaction [Digoxin results in increased expression of ABCB1 protein]; manidipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; mepirodipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Nicardipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; nilvadipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Nisoldipine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; nobiletin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; ophiobolin A inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Propranolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; rhodioloside affects the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; sciadopitysin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; sinensetin analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; sinensetin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; spinosad inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; tangeretin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; terpinolene inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin] [P-glycoprotein inducer and activator TX5 results in increased activity of ABCB1 protein] which results in increased export of Digoxin; Acetaminophen promotes the reaction [ABCB1 protein results in increased transport of Digoxin] ABCB1A protein results in increased uptake of Digoxin ABCB1 protein affects the secretion of Digoxin Digoxin binds to ABCB1 protein ABCB1 gene SNP affects the abundance of Digoxin Digoxin results in increased expression of ABCB1 mRNA; Digoxin results in increased expression of ABCB1 protein ABCB1 gene SNP affects the transport of Digoxin; ABCB1 protein affects the transport of Digoxin |
CTD |
PMID:10527640 PMID:10562306 PMID:10617675 PMID:10997946 PMID:11231118 PMID:11895100 PMID:15276087 PMID:15856409 PMID:15890377 PMID:15969931 PMID:16221533 PMID:16671962 PMID:16674925 PMID:16904803 PMID:17365992 PMID:18385293 PMID:19505989 PMID:19647009 PMID:19958760 PMID:21240898 PMID:21311904 PMID:21321059 PMID:21341280 PMID:23104431 PMID:23976943 PMID:24380838 PMID:25844889 PMID:26888941 PMID:30790579 PMID:31756430 PMID:32003934 More...
|
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects uptake |
EXP |
ABCB1B protein affects the uptake of Digoxin |
CTD |
PMID:10562306 |
|
NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
decreases activity |
ISO |
Digoxin results in decreased activity of ABCG2 protein |
CTD |
PMID:15365089 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased secretion of ALPL protein] |
CTD |
PMID:36329302 |
|
NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695
|
|
G |
Atp1a2 |
ATPase, Na+/K+ transporting, alpha 2 polypeptide |
decreases expression multiple interactions |
ISO |
Digoxin results in decreased expression of ATP1A2 mRNA N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in decreased expression of ATP1A2 mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 1:172,099,276...172,125,631
Ensembl chr 1:172,099,276...172,125,631
|
|
G |
Atp1a3 |
ATPase, Na+/K+ transporting, alpha 3 polypeptide |
decreases expression multiple interactions |
ISO |
Digoxin results in decreased expression of ATP1A3 mRNA N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in decreased expression of ATP1A3 mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Digoxin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Digoxin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Digoxin results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCL10 mRNA]; Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCL10 protein] |
CTD |
PMID:36329302 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
decreases expression increases expression |
ISO |
Digoxin results in decreased expression of CXCL8 protein Digoxin results in increased expression of CXCL8 mRNA |
CTD |
PMID:20116850 PMID:29594315 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCL9 mRNA]; Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCL9 protein] |
CTD |
PMID:36329302 |
|
NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCR3 mRNA]; Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of CXCR3 protein] |
CTD |
PMID:36329302 |
|
NCBI chr X:100,775,141...100,777,753
Ensembl chr X:100,775,141...100,777,875
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of EGR1 mRNA]; Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of EGR1 protein] |
CTD |
PMID:36329302 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Fancd2 |
Fanconi anemia, complementation group D2 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCD2 protein] |
CTD |
PMID:24124520 |
|
NCBI chr 6:113,508,622...113,573,981
Ensembl chr 6:113,508,643...113,573,978
|
|
G |
Fanci |
Fanconi anemia, complementation group I |
multiple interactions |
ISO |
Digoxin inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCI protein] |
CTD |
PMID:24124520 |
|
NCBI chr 7:79,042,056...79,100,013
Ensembl chr 7:79,041,677...79,100,012
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
decreases activity |
ISO |
Digoxin results in decreased activity of G6PD protein |
CTD |
PMID:26820767 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
Digoxin results in increased expression of GFAP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1, soluble |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased secretion of GOT1 protein] |
CTD |
PMID:36329302 |
|
NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased secretion of GPT protein] |
CTD |
PMID:36329302 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsr |
glutathione reductase |
decreases activity |
ISO |
Digoxin results in decreased activity of GSR protein |
CTD |
PMID:26820767 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions increases activity affects localization |
ISO |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Digoxin affects the localization of HIF1A protein]; 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [Digoxin results in increased phosphorylation of HIF1A protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole inhibits the reaction [Digoxin affects the localization of HIF1A protein]; Digoxin results in increased phosphorylation of and results in increased expression of HIF1A protein; KN 93 inhibits the reaction [Digoxin affects the localization of HIF1A protein]; KN 93 inhibits the reaction [Digoxin results in increased phosphorylation of HIF1A protein] Digoxin results in increased activity of HIF1A protein |
CTD |
PMID:19647009 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of ICAM1 mRNA] |
CTD |
PMID:36329302 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA]; Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A protein] |
CTD |
PMID:22292739 |
|
NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Digoxin co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il23r |
interleukin 23 receptor |
multiple interactions |
EXP |
Digoxin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL23R mRNA] |
CTD |
PMID:22292739 |
|
NCBI chr 6:67,399,906...67,468,838
Ensembl chr 6:67,399,916...67,468,839
|
|
G |
Il6ra |
interleukin 6 receptor, alpha |
decreases expression |
ISO |
Digoxin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 3:89,776,631...89,820,503
Ensembl chr 3:89,771,366...89,820,503
|
|
G |
Ins2 |
insulin II |
decreases response to substance |
ISO |
INS protein results in decreased susceptibility to Digoxin |
CTD |
PMID:22562035 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions affects response to substance decreases expression decreases activity |
ISO |
Astemizole inhibits the reaction [Digoxin results in decreased activity of KCNH2 protein]; Astemizole inhibits the reaction [Digoxin results in decreased metabolism of KCNH2 protein modified form]; Sodium deficiency inhibits the reaction [Digoxin results in decreased expression of KCNH2 protein] KCNH2 gene affects the susceptibility to Digoxin Digoxin results in decreased expression of KCNH2 protein modified form |
CTD |
PMID:19139152 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19687166 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Digoxin results in increased phosphorylation of MAPK3 protein N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19687166 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
decreases response to substance |
EXP |
NOS3 protein results in decreased susceptibility to Digoxin |
CTD |
PMID:11761419 |
|
NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472
|
|
G |
Nppa |
natriuretic peptide type A |
multiple interactions increases expression |
ISO |
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased expression of NPPA mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536
|
|
G |
Nppb |
natriuretic peptide type B |
increases expression |
ISO |
Digoxin results in increased expression of NPPB protein |
CTD |
PMID:16032632 |
|
NCBI chr 4:148,070,264...148,071,662
Ensembl chr 4:148,070,245...148,071,662
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
Digoxin results in decreased activity of PGD protein |
CTD |
PMID:26820767 |
|
NCBI chr 4:149,234,448...149,251,162
Ensembl chr 4:149,234,448...149,251,228
|
|
G |
Rorc |
RAR-related orphan receptor gamma |
decreases activity multiple interactions |
EXP |
Digoxin results in decreased activity of RORC protein Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of RORC mRNA]; Digoxin inhibits the reaction [Ethinyl Estradiol results in increased expression of RORC protein] |
CTD |
PMID:21441909 PMID:36329302 |
|
NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583
|
|
G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716
|
|
G |
Slc22a3 |
solute carrier family 22 (organic cation transporter), member 3 |
multiple interactions |
ISO |
Digoxin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr17:12,638,859...12,726,591
Ensembl chr17:12,637,847...12,726,591
|
|
G |
Slc9a1 |
solute carrier family 9 (sodium/hydrogen exchanger), member 1 |
increases expression multiple interactions |
ISO |
Digoxin results in increased expression of SLC9A1 mRNA N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine inhibits the reaction [Digoxin results in increased expression of SLC9A1 mRNA] |
CTD |
PMID:19687166 |
|
NCBI chr 4:133,097,022...133,151,013
Ensembl chr 4:133,097,017...133,151,013
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions increases uptake decreases activity affects transport |
EXP ISO |
Digoxin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite]; Elacridar affects the reaction [SLCO1A4 protein affects the transport of Digoxin] SLCO1A4 protein results in increased uptake of Digoxin Digoxin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin]; Quinine inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin]; Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Digoxin results in decreased activity of SLCO1A4 protein |
CTD |
PMID:11883641 PMID:19833843 PMID:34619012 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
EXP |
Digoxin inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLCO1B2 mRNA] |
CTD |
PMID:36329302 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
Digoxin inhibits the reaction [TARDBP protein binds to TARDBP protein] |
CTD |
PMID:23891805 |
|
NCBI chr 4:148,696,839...148,711,672
Ensembl chr 4:148,696,839...148,711,476
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Digoxin results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions |
ISO |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
decreases expression |
ISO |
dioscin results in decreased expression of ABCB1 mRNA; dioscin results in decreased expression of ABCB1 protein |
CTD |
PMID:24680847 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions |
ISO |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein] |
CTD |
PMID:27317372 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADM protein] |
CTD |
PMID:24146112 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Acads |
acyl-Coenzyme A dehydrogenase, short chain |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADS protein] |
CTD |
PMID:24146112 |
|
NCBI chr 5:115,248,358...115,257,405
Ensembl chr 5:115,248,358...115,257,405
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 8:46,924,214...46,989,088
Ensembl chr 8:46,924,074...46,989,088
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr19:55,240,298...55,285,060
Ensembl chr19:55,240,370...55,286,152
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
multiple interactions |
EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein] |
CTD |
PMID:35481609 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases expression |
ISO EXP |
dioscin inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein] dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein] dioscin results in decreased expression of AKT1 mRNA |
CTD |
PMID:25111127 PMID:29990575 PMID:35481609 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase family 7, member A1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ALDH7A1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr18:56,657,794...56,706,112
Ensembl chr18:56,642,759...56,706,023
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
dioscin results in decreased expression of APAF1 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of ATF6 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
dioscin results in increased expression of BAD mRNA |
CTD |
PMID:33359023 |
|
NCBI chr19:6,919,229...6,929,273
Ensembl chr19:6,919,229...6,929,267
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
EXP ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAK1 protein] dioscin results in increased expression of BAK1 mRNA; dioscin results in increased expression of BAK1 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:29990575 PMID:33359023 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions increases expression |
EXP ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAX protein] dioscin results in increased expression of BAX mRNA; dioscin results in increased expression of BAX protein |
CTD |
PMID:22334414 PMID:22939915 PMID:33359023 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
increases expression |
ISO |
dioscin results in increased expression of BBC3 mRNA; dioscin results in increased expression of BBC3 protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions increases expression decreases expression |
EXP ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] dioscin results in increased expression of BCL2 protein dioscin results in decreased expression of BCL2 mRNA; dioscin results in decreased expression of BCL2 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24742230 PMID:29990575 PMID:33359023 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression |
ISO |
dioscin results in decreased expression of BCL2L1 mRNA; dioscin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions decreases expression |
EXP ISO |
[Acetaminophen co-treated with dioscin] results in increased expression of BID protein dioscin results in decreased expression of BID mRNA; dioscin results in decreased expression of BID protein |
CTD |
PMID:22334414 PMID:22939915 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
dioscin results in increased expression of BIRC5 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases expression increases activity |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP3 protein] dioscin results in decreased expression of CASP3 mRNA; dioscin results in decreased expression of CASP3 protein benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein] dioscin results in increased expression of CASP3 mRNA; dioscin results in increased expression of CASP3 protein dioscin results in increased activity of CASP3 protein |
CTD |
PMID:22334414 PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
dioscin results in increased expression of CASP7 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
increases activity decreases expression multiple interactions increases expression |
ISO |
dioscin results in increased activity of CASP8 protein dioscin results in decreased expression of CASP8 mRNA dioscin results in decreased expression of and results in increased cleavage of CASP8 protein dioscin results in increased expression of CASP8 mRNA; dioscin results in increased expression of CASP8 protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions decreases expression increases expression |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP9 protein] dioscin results in decreased expression of CASP9 mRNA; dioscin results in decreased expression of CASP9 protein dioscin results in increased expression of CASP9 mRNA; dioscin results in increased expression of CASP9 protein |
CTD |
PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNA2 mRNA; dioscin results in decreased expression of CCNA2 protein |
CTD |
PMID:33359023 |
|
NCBI chr 3:36,619,014...36,627,187
Ensembl chr 3:36,619,014...36,626,299
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNB1 mRNA; dioscin results in decreased expression of CCNB1 protein |
CTD |
PMID:29990575 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases expression |
ISO |
dioscin results in increased expression of CCND1 mRNA dioscin results in decreased expression of CCND1 mRNA; dioscin results in decreased expression of CCND1 protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNE1 mRNA; dioscin results in decreased expression of CCNE1 protein |
CTD |
PMID:33359023 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK1 mRNA; dioscin results in decreased expression of CDK1 protein |
CTD |
PMID:29990575 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK2 mRNA; dioscin results in decreased expression of CDK2 protein |
CTD |
PMID:33359023 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdk4 |
cyclin dependent kinase 4 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK4 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789
|
|
G |
Cdk6 |
cyclin dependent kinase 6 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK6 mRNA; dioscin results in decreased expression of CDK6 protein |
CTD |
PMID:33359023 |
|
NCBI chr 5:3,391,004...3,581,008
Ensembl chr 5:3,391,485...3,581,008
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO |
dioscin results in increased expression of CDKN1A mRNA; dioscin results in increased expression of CDKN1A protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
increases expression |
ISO |
dioscin results in increased expression of CDKN1B mRNA; dioscin results in increased expression of CDKN1B protein |
CTD |
PMID:33359023 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn2a |
cyclin dependent kinase inhibitor 2A |
increases expression |
ISO |
dioscin results in increased expression of CDKN2A mRNA; dioscin results in increased expression of CDKN2A protein |
CTD |
PMID:33359023 |
|
NCBI chr 4:89,192,710...89,212,856
Ensembl chr 4:89,192,708...89,212,890
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK1 mRNA; dioscin results in decreased expression of CHEK1 protein |
CTD |
PMID:33359023 |
|
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chek2 |
checkpoint kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK2 mRNA; dioscin results in decreased expression of CHEK2 protein |
CTD |
PMID:29990575 |
|
NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
EXP ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of CTNNB1 mRNA] dioscin results in increased expression of CTNNB1 protein dioscin results in increased expression of CTNNB1 mRNA; dioscin results in increased expression of CTNNB1 protein |
CTD |
PMID:24742230 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
dioscin results in increased expression of CYCS mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
increases expression |
ISO |
dioscin results in increased expression of CYP2C9 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of and results in increased activity of CYP2E1 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr15:76,386,215...76,396,167
Ensembl chr15:76,386,215...76,396,153
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT2 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 7:98,802,870...98,831,920
Ensembl chr 7:98,802,865...98,831,926
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
ISO |
dioscin results in increased expression of DIABLO mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
increases expression multiple interactions |
EXP ISO |
dioscin results in increased expression of ESR1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of ESR1 protein] |
CTD |
PMID:24742230 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
increases expression multiple interactions |
ISO EXP |
dioscin results in increased expression of ESR2 protein fulvestrant inhibits the reaction [dioscin results in increased expression of ESR2 protein] |
CTD |
PMID:24742230 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of FADD mRNA; dioscin results in increased expression of FADD protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
dioscin results in increased expression of FAS mRNA; dioscin results in increased expression of FAS protein |
CTD |
PMID:22334414 PMID:33359023 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
increases expression |
ISO |
dioscin results in increased expression of FASLG mRNA; dioscin results in increased expression of FASLG protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression |
ISO |
dioscin results in increased expression of FOXO1 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:27317372 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of GSR protein] |
CTD |
PMID:24146112 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] dioscin inhibited the reaction [thioacetamide increased expression of Hmgb1 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein] dioscin inhibited the reaction [thioacetamide decreased expression of Hmox1 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of HSPA5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Icam1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein] |
CTD |
PMID:35481609 |
|
NCBI chr11:53,522,150...53,525,529
Ensembl chr11:53,522,151...53,525,529
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]] dioscin inhibited the reaction [thioacetamide increased expression of IL-1b mRNA in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein] |
CTD |
PMID:35481609 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein] |
CTD |
PMID:35481609 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA] dioscin inhibited the reaction [thioacetamide increased expression of IL-6 mRNA in liver] dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]] |
CTD RGD |
PMID:24146112 PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Kdr |
kinase insert domain protein receptor |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein] |
CTD |
PMID:25111127 |
|
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Keap1 |
kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Doxorubicin results in increased expression of KEAP1 protein] |
CTD |
PMID:28082111 |
|
NCBI chr 9:21,141,026...21,150,628
Ensembl chr 9:21,141,026...21,150,657
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of KRT18 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of KRT18 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr15:101,936,651...101,940,461
Ensembl chr15:101,936,615...101,940,462
|
|
G |
Lrp5 |
low density lipoprotein receptor-related protein 5 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [dioscin results in increased expression of LRP5 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr19:3,634,825...3,736,574
Ensembl chr19:3,634,828...3,736,564
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK1 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK3 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
dioscin results in increased expression of MAPK8 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression |
ISO |
dioscin results in increased expression of MAPK9 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mdh1 |
malate dehydrogenase 1, NAD (soluble) |
multiple interactions |
EXP |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of MDH1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr11:21,506,692...21,521,934
Ensembl chr11:21,506,692...21,522,367
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
dioscin results in decreased expression of MTOR mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Muc5ac |
mucin 5, subtypes A and C, tracheobronchial/gastric |
multiple interactions |
EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA] |
CTD |
PMID:35481609 |
|
NCBI chr 7:141,342,695...141,372,964
Ensembl chr 7:141,342,709...141,372,968
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of and affects the localization of NFE2L2 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]] dioscin inhibited the reaction [thioacetamide decreased expression of Nfe2L2 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Nfkb1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
decreases degradation |
ISO |
dioscin results in decreased degradation of NFKBIA protein |
CTD |
PMID:24680847 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Nqo1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression |
ISO |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NR0B2 mRNA] dioscin results in increased expression of NR0B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of NR1H4 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] dioscin inhibited the reaction [thioacetamide decreased expression of Nr1h4 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
multiple interactions decreases expression increases expression |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of PARP1 protein] dioscin results in decreased expression of PARP1 mRNA; dioscin results in decreased expression of PARP1 protein dioscin results in increased expression of PARP1 mRNA |
CTD |
PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
decreases expression |
ISO |
dioscin results in decreased expression of PIK3CB mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 9:98,920,455...99,022,264
Ensembl chr 9:98,918,707...99,022,674
|
|
G |
Pnp2 |
purine-nucleoside phosphorylase 2 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PNP protein] |
CTD |
PMID:22939915 |
|
NCBI chr14:51,193,598...51,202,206
Ensembl chr14:51,193,449...51,202,206
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of PPARA protein] |
CTD |
PMID:24146112 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PRDX1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Prkaa1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkab1 |
protein kinase, AMP-activated, beta 1 non-catalytic subunit |
increases expression |
ISO |
dioscin results in increased expression of PRKAB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 5:116,151,654...116,162,449
Ensembl chr 5:116,151,645...116,162,567
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Ptgs2 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Ptk2 |
PTK2 protein tyrosine kinase 2 |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:25111127 |
|
NCBI chr15:73,076,951...73,297,192
Ensembl chr15:73,076,951...73,295,129
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]] |
CTD |
PMID:28082111 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rgn |
regucalcin |
multiple interactions |
EXP |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of RGN protein] |
CTD |
PMID:22939915 |
|
NCBI chr X:20,413,980...20,428,328
Ensembl chr X:20,416,026...20,428,328
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
decreases expression |
ISO |
dioscin results in decreased expression of RPS6KB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:27317372 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
ISO |
dioscin results in increased expression of SLCO1A2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 mRNA]; dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 protein] dioscin results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Suox |
sulfite oxidase |
multiple interactions |
EXP |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of SUOX protein] |
CTD |
PMID:22939915 |
|
NCBI chr10:128,505,756...128,509,787
Ensembl chr10:128,505,763...128,509,942
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein] dioscin inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35481609 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA] dioscin inhibited the reaction [thioacetamide increased expression of Tnfa mRNA in liver] dioscin results in increased expression of TNF mRNA; dioscin results in increased expression of TNF protein dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] |
CTD RGD |
PMID:22334414 PMID:24146112 PMID:28082111 PMID:29990575 PMID:33359023 PMID:35481609 PMID:29091898 More...
|
RGD:15090820 |
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF1A mRNA; dioscin results in increased expression of TNFRSF1A protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfrsf25 |
tumor necrosis factor receptor superfamily, member 25 |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 4:152,199,985...152,204,568
Ensembl chr 4:152,200,391...152,204,576
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
decreases expression multiple interactions |
EXP |
dioscin results in decreased expression of TNFSF11 mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFSF11 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of TRADD mRNA |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 8:105,985,207...105,991,226
Ensembl chr 8:105,984,918...105,991,241
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
dioscin results in increased expression of TRAF1 protein |
CTD |
PMID:22334414 |
|
NCBI chr 2:34,831,762...34,851,784
Ensembl chr 2:34,831,762...34,851,784
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions increases expression |
EXP ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of TRP53 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TRP53 protein] dioscin results in increased expression of TP53 mRNA; dioscin results in increased expression of TP53 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24146112 PMID:29990575 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Wee1 |
WEE 1 homolog 1 (S. pombe) |
increases expression |
ISO |
dioscin results in increased expression of WEE1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493
|
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
multiple interactions increases expression |
ISO |
[Ethinyl Estradiol co-treated with Diosgenin] results in increased expression of ABCC2 mRNA Diosgenin results in increased expression of ABCC2 mRNA |
CTD |
PMID:16105132 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C member 3 |
increases expression multiple interactions |
ISO |
Diosgenin results in increased expression of ABCC3 mRNA [Ethinyl Estradiol co-treated with Diosgenin] results in increased expression of ABCC3 mRNA |
CTD |
PMID:16105132 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
ISO EXP |
Diosgenin results in increased expression of ABCG5 mRNA [Diosgenin results in increased expression of ABCG5 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol co-treated with Diosgenin] results in decreased expression of ABCG5 mRNA Diosgenin promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol] |
CTD |
PMID:12963437 PMID:15611112 PMID:16105132 |
|
NCBI chr17:84,965,602...84,990,439
Ensembl chr17:84,965,662...84,990,439
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions increases expression |
ISO EXP |
[Diosgenin results in increased expression of ABCG8 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol co-treated with Diosgenin] results in decreased expression of ABCG8 mRNA Diosgenin promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol] |
CTD |
PMID:12963437 PMID:15611112 PMID:16105132 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
decreases expression |
ISO |
Diosgenin results in decreased expression of ACACA mRNA |
CTD |
PMID:32347045 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007
|
|
G |
Adam17 |
a disintegrin and metallopeptidase domain 17 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 protein] |
CTD |
PMID:35305976 |
|
NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased activity of AKT1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of APAF1 protein]]; Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of APAF1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr10:90,825,173...90,918,688
Ensembl chr10:90,825,173...90,918,632
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
[morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of BAX protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of BAX protein] |
CTD |
PMID:28106847 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2 protein] [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Diosgenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein] Diosgenin results in decreased expression of BCL2 protein |
CTD |
PMID:16331273 PMID:28106847 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2a1b |
B cell leukemia/lymphoma 2 related protein A1b |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of BCL2A1 protein Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of BCL2L1 protein Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions decreases expression |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] Diosgenin results in decreased expression of BIRC2 protein |
CTD |
PMID:16331273 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP3 protein] [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein] |
CTD |
PMID:28106847 PMID:35149085 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP9 protein]]; 3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP9 protein]]; Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP9 protein]; Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP9 protein]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in increased expression of CASP9 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
EXP |
Diosgenin results in decreased expression of CCL2 mRNA Diosgenin inhibits the reaction [Dietary Fats results in increased expression of CCL2 mRNA] |
CTD |
PMID:26408789 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of CCND1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
Diosgenin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Diosgenin affects the reaction [Dietary Fats affects the expression of CES1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of CFLAR protein Diosgenin inhibits the reaction [TNF protein results in increased expression of CFLAR protein] |
CTD |
PMID:16331273 |
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
EXP |
Diosgenin results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:26408789 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Diosgenin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 1:74,752,311...74,777,056
Ensembl chr 1:74,752,733...74,777,051
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
increases expression |
EXP |
Diosgenin results in increased expression of CYP3A11 mRNA |
CTD |
PMID:15611112 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Cyp7a1 |
cytochrome P450, family 7, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Ethinyl Estradiol co-treated with Diosgenin] results in increased expression of CYP7A1 mRNA; Diosgenin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Diosgenin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein] |
CTD |
PMID:12963437 PMID:33383043 |
|
NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
ISO |
Diosgenin affects the reaction [alpha-Chlorohydrin affects the localization of DNM1L protein] Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of DNM1L protein] |
CTD |
PMID:35149085 |
|
NCBI chr16:16,130,092...16,176,863
Ensembl chr16:16,130,094...16,176,823
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of EIF4EBP1 protein]]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions increases expression |
EXP |
Diosgenin inhibits the reaction [Dietary Fats results in decreased expression of ESR2 protein]; Diosgenin promotes the reaction [RXRA protein binds to ESR2 protein] Diosgenin results in increased expression of ESR2 protein |
CTD |
PMID:26408789 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
decreases expression multiple interactions |
EXP |
Diosgenin results in decreased expression of FABP4 mRNA Diosgenin inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA]; fulvestrant inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA]; PPARG protein inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA]; rosiglitazone inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA] |
CTD |
PMID:26408789 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Diosgenin results in decreased expression of FAS mRNA |
CTD |
PMID:32347045 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fgf15 |
fibroblast growth factor 15 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of FIS1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 5:136,982,129...136,995,088
Ensembl chr 5:136,982,129...136,995,088
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:35305976 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
Diosgenin inhibits the reaction [Dietary Fats results in increased expression of IL6 mRNA] Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] Diosgenin results in decreased expression of IL6 mRNA |
CTD |
PMID:26408789 PMID:35305976 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of INS1 protein]; Diosgenin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:24001619 PMID:35305976 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Lipc |
lipase, hepatic |
increases activity |
ISO |
Diosgenin results in increased activity of LIPC protein |
CTD |
PMID:20149787 |
|
NCBI chr 9:70,705,410...70,859,503
Ensembl chr 9:70,705,410...70,859,508
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases lipidation multiple interactions |
ISO |
Diosgenin results in decreased lipidation of MAP1LC3B protein [alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein; alpha-Chlorohydrin inhibits the reaction [Diosgenin results in decreased lipidation of MAP1LC3B protein] 3-methyladenine inhibits the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; [alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein; alpha-Chlorohydrin inhibits the reaction [Diosgenin results in decreased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:35149085 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Mesp1 |
mesoderm posterior 1 |
decreases expression |
ISO |
Diosgenin results in decreased expression of MESP1 mRNA; Diosgenin results in decreased expression of MESP1 protein |
CTD |
PMID:34806916 |
|
NCBI chr 7:79,441,989...79,443,338
Ensembl chr 7:79,441,989...79,443,536
|
|
G |
Mest |
mesoderm specific transcript |
multiple interactions decreases expression |
EXP |
Diosgenin inhibits the reaction [Dietary Fats results in increased expression of MEST mRNA] Diosgenin results in decreased expression of MEST mRNA |
CTD |
PMID:26408789 |
|
NCBI chr 6:30,733,505...30,783,580
Ensembl chr 6:30,723,546...30,748,464
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in decreased expression of MFN1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 3:32,583,594...32,633,384
Ensembl chr 3:32,583,614...32,633,388
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in decreased expression of MFN2 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 4:147,958,043...147,989,527
Ensembl chr 4:147,958,056...147,989,161
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity increases expression |
ISO |
Diosgenin results in increased activity of MMP2 protein Diosgenin results in increased expression of MMP2 mRNA |
CTD |
PMID:21814480 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression decreases activity |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of MMP9 protein] Diosgenin results in decreased expression of MMP9 mRNA Diosgenin results in decreased activity of MMP9 protein |
CTD |
PMID:16331273 PMID:21814480 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of MTOR protein]]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:35149085 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of MYC protein] |
CTD |
PMID:16331273 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16331273 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Diosgenin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Diosgenin affects the reaction [Dietary Fats affects the expression of NR1H4 protein] |
CTD |
PMID:33383043 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
EXP |
Diosgenin results in increased activity of NR1I2 protein |
CTD |
PMID:15611112 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
increases expression decreases response to substance decreases expression multiple interactions |
EXP ISO |
Diosgenin results in increased expression of PPARG protein Diosgenin results in increased expression of PPARG mRNA PPARG protein results in decreased susceptibility to Diosgenin Diosgenin results in decreased expression of PPARG mRNA [Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]] which results in decreased activity of PPARG protein; Diosgenin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA]; Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]; fulvestrant inhibits the reaction [Diosgenin results in decreased expression of PPARG mRNA]; PPARG protein inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA]; PPARG protein inhibits the reaction [Diosgenin results in decreased expression of PPARG mRNA] |
CTD |
PMID:24001619 PMID:26408789 PMID:32347045 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein] Diosgenin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] |
CTD |
PMID:16331273 PMID:35305976 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rhbdf2 |
rhomboid 5 homolog 2 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [Streptozocin results in increased expression of RHBDF2 mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of RHBDF2 protein] |
CTD |
PMID:35305976 |
|
NCBI chr11:116,488,991...116,517,786
Ensembl chr11:116,488,991...116,517,845
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of RPS6KB1 protein]; [Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:35149085 |
|
NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
EXP |
[Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]] which results in decreased activity of PPARG protein; Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]; Diosgenin promotes the reaction [RXRA protein binds to ESR2 protein] |
CTD |
PMID:26408789 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Diosgenin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 5:125,354,151...125,418,082
Ensembl chr 5:125,354,151...125,418,158
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in decreased phosphorylation of STK11 protein] |
CTD |
PMID:35149085 |
|
NCBI chr10:79,951,602...79,966,513
Ensembl chr10:79,951,637...79,966,516
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases activity |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Diosgenin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of MYC protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] Diosgenin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of TNF protein] Diosgenin results in decreased activity of TNF protein |
CTD |
PMID:16331273 PMID:35305976 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions decreases activity |
EXP |
Diosgenin inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] Diosgenin results in decreased activity of TNFSF11 protein |
CTD |
PMID:16331273 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Ulk1 |
unc-51 like kinase 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of ULK1 protein]; [Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of ULK1 protein |
CTD |
PMID:35149085 |
|
NCBI chr 5:110,932,355...110,957,991
Ensembl chr 5:110,932,354...110,957,963
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of VEGFA protein] |
CTD |
PMID:16331273 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Wnt10b |
wingless-type MMTV integration site family, member 10B |
decreases expression |
EXP |
Diosgenin results in decreased expression of WNT10B mRNA |
CTD |
PMID:26408789 |
|
NCBI chr15:98,668,593...98,676,093
Ensembl chr15:98,668,593...98,676,031
|
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 1:74,228,862...74,233,867
Ensembl chr 1:74,230,944...74,233,790
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ifng |
interferon gamma |
decreases expression |
EXP |
ginsenoside M1 results in decreased expression of IFNG mRNA |
CTD |
PMID:15914323 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
ginsenoside M1 results in decreased expression of IL1B mRNA |
CTD |
PMID:15914323 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il4 |
interleukin 4 |
decreases expression |
EXP |
ginsenoside M1 results in decreased expression of IL4 mRNA |
CTD |
PMID:15914323 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itga4 |
integrin alpha 4 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467
|
|
G |
Itgal |
integrin alpha L |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgb1 |
integrin beta 1 (fibronectin receptor beta) |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]] |
CTD |
PMID:21875580 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases secretion |
ISO |
ginsenoside M1 results in decreased secretion of MMP9 protein |
CTD |
PMID:21875580 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
ISO |
ginsenoside M1 results in decreased expression of and results in decreased activity of NOS2 protein |
CTD |
PMID:15802804 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
multiple interactions |
ISO |
[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,845,581...122,867,802
Ensembl chr 5:122,845,607...122,867,801
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
decreases response to substance |
EXP |
P2RX7 gene mutant form results in decreased susceptibility to ginsenoside M1 |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP ISO |
ginsenoside M1 results in decreased expression of PTGS2 mRNA ginsenoside M1 results in decreased expression of PTGS2 protein |
CTD |
PMID:15802804 PMID:15914323 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein] |
CTD |
PMID:15802804 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Sele |
selectin, endothelial cell |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:21875580 |
|
NCBI chr 1:163,867,200...163,886,056
Ensembl chr 1:163,875,773...163,885,246
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] ginsenoside M1 results in decreased expression of TNF mRNA ginsenoside M1 results in decreased susceptibility to TNF protein |
CTD |
PMID:15914323 PMID:21875580 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:21875580 |
|
NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337
|
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased expression of CXCL8 mRNA]; ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of CXCL8 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein] |
CTD |
PMID:29412148 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions |
ISO |
ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:24380838 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19781563 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Atp6v1a |
ATPase, H+ transporting, lysosomal V1 subunit A |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1A mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr16:43,905,765...43,960,055
Ensembl chr16:43,905,765...43,960,068
|
|
G |
Atp6v1b2 |
ATPase, H+ transporting, lysosomal V1 subunit B2 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1B2 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 8:69,541,388...69,566,370
Ensembl chr 8:69,541,298...69,566,363
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions increases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 2:133,394,079...133,404,816
Ensembl chr 2:133,394,079...133,404,805
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein] |
CTD |
PMID:38373586 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein] |
CTD |
PMID:19781563 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Clcn7 |
chloride channel, voltage-sensitive 7 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CLCN7 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr17:25,352,353...25,381,077
Ensembl chr17:25,352,365...25,381,078
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSB mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSD mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
EXP ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein] |
CTD |
PMID:38373586 |
|
NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein |
CTD |
PMID:19781563 PMID:25422538 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions increases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL18 protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL18 protein] |
CTD |
PMID:38373586 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL1B protein] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL1B protein] |
CTD |
PMID:38373586 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:17655881 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itgam |
integrin alpha M |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein] |
CTD |
PMID:17655881 |
|
NCBI chr 7:127,661,812...127,717,663
Ensembl chr 7:127,661,812...127,717,663
|
|
G |
Itgb2 |
integrin beta 2 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein] |
CTD |
PMID:17655881 |
|
NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542
|
|
G |
Kcne1 |
potassium voltage-gated channel, Isk-related subfamily, member 1 |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of KCNE1 |
CTD |
PMID:24615935 |
|
NCBI chr16:92,142,889...92,156,356
Ensembl chr16:92,142,870...92,156,356
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
affects activity |
ISO |
ginsenoside Rb1 affects the activity of KCNH2 protein |
CTD |
PMID:15842772 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of LAMP1 mRNA] |
CTD |
PMID:34812491 |
|
NCBI chr 8:13,209,161...13,225,338
Ensembl chr 8:13,209,161...13,225,338
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein] |
CTD |
PMID:38373586 |
|
NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP ISO |
ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]]; ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein] |
CTD |
PMID:38373586 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
ginsenoside Rb1 results in increased expression of MAP2 mRNA |
CTD |
PMID:24599032 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Nfatc1 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr18:80,649,418...80,756,286
Ensembl chr18:80,649,420...80,756,286
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions affects localization increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA |
CTD |
PMID:19781563 PMID:22780686 PMID:25422538 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein] |
CTD |
PMID:38373586 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
P2rx4 |
purinergic receptor P2X, ligand-gated ion channel 4 |
multiple interactions |
ISO |
ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:30545933 |
|
NCBI chr 5:122,845,581...122,867,802
Ensembl chr 5:122,845,607...122,867,801
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
ginsenoside Rb1 results in increased expression of PGR protein |
CTD |
PMID:16204943 |
|
NCBI chr 9:8,890,017...8,968,612
Ensembl chr 9:8,899,834...8,968,612
|
|
G |
Pink1 |
PTEN induced putative kinase 1 |
multiple interactions |
EXP ISO |
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein] Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]] |
CTD |
PMID:38373586 |
|
NCBI chr 4:138,040,718...138,053,631
Ensembl chr 4:138,040,720...138,053,618
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]] |
CTD |
PMID:38373586 |
|
NCBI chr17:11,059,227...12,282,257
Ensembl chr17:11,059,271...12,282,248
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein] |
CTD |
PMID:22386813 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Runx2 |
runt related transcription factor 2 |
increases expression multiple interactions |
ISO |
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA] |
CTD |
PMID:27470910 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family, member 1b2 |
multiple interactions |
ISO |
ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein |
CTD |
PMID:25297453 |
|
NCBI chr 6:141,575,178...141,632,372
Ensembl chr 6:141,575,244...141,632,372
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
ISO |
ginsenoside Rb1 results in decreased expression of SQSTM1 protein Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]] |
CTD |
PMID:34812491 PMID:38373586 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Tfeb |
transcription factor EB |
multiple interactions |
ISO EXP |
[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA] ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]] |
CTD |
PMID:34812491 PMID:38373586 |
|
NCBI chr17:48,047,962...48,103,341
Ensembl chr17:48,047,955...48,103,344
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA |
CTD |
PMID:27470910 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] |
CTD |
PMID:22386813 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
multiple interactions decreases response to substance |
EXP |
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein |
CTD |
PMID:22386813 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
ISO |
ginsenoside Rb2 results in increased expression of ABCC2 mRNA |
CTD |
PMID:23835644 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|